STOCK TITAN
  1. Home
  2. Sec-filings
  3. IPA
  4. [6-K] MindWalk Holdings Corp. Current Report (Foreign Issuer)

MindWalk (NASDAQ: HYFT) CEO joins Jones AI Day panel on AI drug discovery

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

MindWalk Holdings Corp. filed a Form 6-K highlighting a press release that its President and CEO, Dr. Jennifer Bath, will join a Jones AI Day virtual panel on June 15, 2026, focused on the future of AI-driven drug discovery.

The event will examine how high-performance compute, native biological knowledge representations, and generative and agentic AI can address long-standing drug discovery challenges. MindWalk describes its HYFT® system, which powers ReefIQ™, as a biological context layer built on 25 years of wet-lab expertise, organizing 660 million biological patterns and 25 billion relationships.

Its LensAI™ platform runs on this infrastructure to support target discovery, candidate diligence, portfolio decisions, and agentic AI workflows. MindWalk notes LensAI is already used in contracted, recurring arrangements with life-sciences customers and includes extensive forward-looking statements language outlining assumptions and risks around adoption, infrastructure, competition, and regulation.

Positive

  • None.

Negative

  • None.
Event date and time June 15, 2026, 12:00 p.m. ET Jones AI Day virtual panel timing
Event duration window 10:30 a.m. to 2:30 p.m. ET Jones AI Day overall schedule
Biological patterns 660 million patterns Scale of HYFT-powered biological representation
Biological relationships 25 billion relationships Connections in MindWalk’s knowledge representation
Wet-lab expertise 25 years Experience foundation for MindWalk’s AI systems
Curation history 20 years Time over which the biological representation was refined
Bio-Native AI technical
"MindWalk Holdings Corp. (NASDAQ: HYFT) is a Bio-Native AI company"
agentic AI technical
"the BioIntelligence infrastructure that life sciences AI and agentic AI require"
Agentic AI refers to computer systems that can make their own decisions and take actions without needing someone to tell them what to do each time. It's like giving a robot a degree of independence to solve problems or achieve goals on its own, which matters because it could change how we work and interact with technology in everyday life.
HYFT technical
"Its HYFT® technology powers ReefIQ™, the biological context layer for life sciences"
ReefIQ technical
"HYFT® system powers ReefIQ™, the biological context layer for life sciences"
LensAI technical
"The LensAI platform operates on this infrastructure to enable target discovery"
forward-looking statements regulatory
"This press release contains “forward-looking statements” within the meaning of applicable"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June, 2026.

 

Commission File Number: 001-39530

 

 

MindWalk Holdings Corp.

3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒

Form 40-F ☐

 

 

 

 

EXHIBIT INDEX

 

 

Exhibit

Description

99.1

 

Press Release dated June 12, 2026

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

MINDWALK HOLDINGS CORP.

Date: June 12, 2026

 

 

 

 

 

By:

/s/ Jennifer Bath

 

Name:

Jennifer Bath

 

Title:

President and Chief Executive Officer

 

 

99.1

MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery

AUSTIN, Texas – June 12, 2026 (BUSINESS WIRE) – MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones, alongside Absci (NASDAQ: ABSI) and a leading AI compute provider, as part of Jones AI Day. The panel, “Partnering to Power the New Era of Drug Discovery,” will be held on Monday, June 15, 2026, at 12:00 p.m. ET.

Moderated by Jones Research Senior Research Analysts Dr. Debanjana Chatterjee and Dr. Danya Ben-Hail, the panel will explore how the convergence of high-performance compute, native biological knowledge representations, and generative AI can dismantle longstanding barriers in drug discovery, including prolonged screening timelines and historically undruggable targets.

MindWalk’s Perspective

MindWalk is a biology company that built AI on top of 25 years of wet-lab expertise. Its HYFT® technology powers ReefIQ™, the biological context layer for life sciences, enriching biological data at ingestion and connecting it across a continuously evolving knowledge representation of 660 million biological patterns and 25 billion relationships, with the LensAI™ platform serving as the reasoning and application layer on top. Because predictions are grounded in evolutionary constraint rather than statistical correlation, the architecture is designed to keep both AI models and autonomous agents from hallucinating in the highest-consequence drug discovery workflows. On the panel, Dr. Bath is expected to discuss why the durable asset in biological AI is the enriched context layer rather than any individual model, and how that layer makes agentic AI trustworthy enough to deploy in regulated workflows. LensAI™ is already in contracted, recurring arrangements with life-sciences customers today.

“The hardest problem in drug discovery was never a shortage of compute or models - it’s that biological data arrives fragmented, and a model reasoning over fragments will confidently get it wrong. Our work grounds that reasoning in what evolution has already constrained, so the biology is connected and real before a model ever acts on it. Paired with compute built for this kind of memory-heavy work, that’s what makes agentic AI trustworthy enough for the highest-consequence workflows. Biology, context, and compute - that convergence is what I’m looking forward to discussing,” said Dr. Jennifer Bath, PhD, Chief Executive Officer and President of MindWalk Holdings Corp.

Panelists

MindWalk (NASDAQ: HYFT): Dr. Jennifer Bath, PhD, Chief Executive Officer and President

Absci (NASDAQ: ABSI): Sean McClain, Founder and Chief Executive Officer

Leading AI compute provider: Senior healthcare and life-science strategy leadership

Event Details

Event: Jones AI Day Virtual Panel, “Partnering to Power the New Era of Drug Discovery”

Date and Time: Monday, June 15, 2026, 12:00 p.m. ET

Format: Hosted as part of Jones AI Day (10:30 a.m. to 2:30 p.m. ET), featuring multiple leading AI drug discovery platforms

Registration: Open to institutional investors through Jones. RSVP to Yuki Gonzalez: ygonzalez@jonestrading.com

About MindWalk Holdings Corp.

MindWalk Holdings Corp. (NASDAQ: HYFT) is a Bio-Native AI company building the BioIntelligence infrastructure that life sciences AI and agentic AI require. Its proprietary HYFT® system powers ReefIQ™, the biological context layer for life sciences — a function-aware representation organized around HYFT pattern-objects that span sequence and structural biology. Refined over 20 years of curation, this continuously evolving knowledge representation of 660 million biological patterns and 25 billion relationships enriches data at ingestion and compounds in analytical value with every program run on the platform. The LensAI platform operates on this infrastructure to enable target discovery, candidate diligence, and portfolio decision support, and to host the agentic AI workflows pharma is racing to deploy. MindWalk’s architecture is designed so that the HYFT representation layer — not any individual AI model — is the durable, compounding competitive asset. References to “MindWalk” in this release refer to MindWalk Holdings Corp. and its subsidiaries, including BioStrand BV, which operates under the MindWalk brand, as the context requires.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of applicable United States securities laws and “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements are often identified by terms such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “targets,” “will,” “is designed to,” or similar expressions, or by statements that certain actions, events, or results are expected, are intended, or will occur or be achieved. Forward-looking statements in this press release include, without limitation, statements regarding: Dr. Bath’s participation in the Jones AI Day virtual panel and the anticipated timing, format, and topics of the event; expectations regarding the convergence of high-performance compute, biological representations, and generative and agentic AI in life sciences; the characterization of the HYFT® system as powering ReefIQ™, the Company’s biological context layer for life sciences, and of LensAI™ as the reasoning and application layer; the characterization of the biological representation and its scale (660 million biological patterns and 25 billion relationships) and of ReefIQ™ enrichment as enriching data at ingestion and compounding in analytical value over time; the design of the Company’s architecture to keep AI models and autonomous agents from hallucinating and to make agentic AI trustworthy enough to deploy in regulated, high-consequence workflows; and the existence, conversion, and expansion of contracted, recurring arrangements with life-sciences customers.

References to Jones, Absci, and the other panelists are descriptive of the event and do not imply

any endorsement, sponsorship, partnership, commercial agreement, or financial relationship, except as expressly stated. Statements, data, or opinions attributable to other panelists or their respective companies—including any analyst rating, price target, or research opinion—are not those of MindWalk, and MindWalk does not adopt, endorse, or undertake to update them.

Forward-looking statements are based on management’s current expectations and on assumptions that management believes are reasonable, including assumptions regarding continued customer demand for and adoption of the Company’s platform, the Company’s ability to maintain and scale its technology and infrastructure (including reliance on third-party compute and cloud providers), and the absence of material adverse changes in its business or markets. Such statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially, including, without limitation: that the event may be rescheduled, modified, or cancelled; that adoption of Bio-Native and agentic AI may be slower than anticipated; the Company’s ability to convert engagement into, and to maintain and expand, contracted recurring arrangements; reliance on third-party compute, cloud, and infrastructure providers; competitive dynamics in AI infrastructure and life sciences; intellectual property risks, including patent prosecution and trademark clearance for the ReefIQ™ name; regulatory determinations; and capital markets conditions. There can be no assurance that any candidate, program, or capability referenced will achieve the results described or will be developed, validated, approved, or commercialized.

Additional information regarding risks and uncertainties is available in MindWalk’s Annual Report on Form 20-F and other filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov/edgar). Forward-looking statements speak only as of the date of this press release. Except as required by law, MindWalk undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Nothing in this press release constitutes investment, legal, or tax advice, and this press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

Trademarks

HYFT® is a registered trademark of MindWalk Holdings Corp. ReefIQ™ and LensAI™ are trademarks of MindWalk Holdings Corp. or its subsidiaries; ReefIQ™ registration is pending. All other trademarks are the property of their respective owners.

Investor Relations Contact

Louie Toma, CPA, CFA

Managing Director, CoreIR

investors@mindwalkai.com

Source: MindWalk Holdings Corp

Source: View Original Filing on SEC EDGAR

FAQ

What did MindWalk Holdings (NASDAQ: HYFT) announce in its June 2026 Form 6-K?

MindWalk announced CEO Dr. Jennifer Bath will join a Jones AI Day virtual panel on June 15, 2026, discussing AI drug discovery. The filing also details the company’s HYFT, ReefIQ, and LensAI platforms and includes standard forward-looking statements and risk disclosures.

What is MindWalk Holdings’ HYFT and ReefIQ technology mentioned in the filing?

HYFT powers ReefIQ, MindWalk’s biological context layer for life sciences built from 25 years of wet-lab expertise. It organizes 660 million biological patterns and 25 billion relationships, enriching data at ingestion to support AI-driven analysis and drug discovery workflows on the LensAI platform.

When is MindWalk’s CEO speaking at the Jones AI Day panel?

Dr. Jennifer Bath is scheduled to speak on a virtual panel titled “Partnering to Power the New Era of Drug Discovery” on Monday, June 15, 2026, at 12:00 p.m. ET. The panel is part of Jones AI Day running from 10:30 a.m. to 2:30 p.m. ET.

How does MindWalk describe its LensAI platform in this Form 6-K disclosure?

LensAI is described as the reasoning and application layer operating on MindWalk’s HYFT-powered ReefIQ infrastructure. It supports target discovery, candidate diligence, portfolio decision support, and hosting agentic AI workflows that life sciences and pharmaceutical companies are working to deploy in regulated environments.

What scale of biological data does MindWalk’s platform handle, according to the filing?

MindWalk states that its biological representation encompasses 660 million biological patterns and 25 billion relationships. This large, curated knowledge base is intended to enrich biological data at ingestion and compound in analytical value as more programs run on the platform over time.

What forward-looking risks does MindWalk highlight in this Form 6-K press release?

The company cites risks such as potential rescheduling of the event, slower-than-anticipated adoption of Bio-Native and agentic AI, reliance on third-party compute and cloud providers, competitive dynamics, intellectual property challenges, regulatory determinations, and capital markets conditions that may cause actual results to differ materially.

Filing Exhibits & Attachments

1 document

Press Releases